This program, born from the Inflation
Reduction Act passed by Democrats last year, has encountered fierce opposition from
pharmaceutical companies. Two manufacturers and industry groups have filed lawsuits,
arguing that the measure violates the Constitution.
However, undeterred by
these challenges, the administration presses forward, determined to implement this
transformative and historic change. By September 1, it plans to announce the first
10 drugs that will undergo negotiation, with the actual negotiation process
scheduled to occur between 2023 and 2024. The newly established prices resulting
from these negotiations will take effect in 2026.
Stay tuned for further
updates on this significant stride towards achieving fairer drug prices for all!
